Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.

Szczegóły
Abstrakt

Tytuł:: Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.
Autorzy:: Kang S; Key Laboratory of Radiation Physics and Technology, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, Sichuan, China (mainland).; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan, China (mainland).
Wu J; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan, China (mainland).
Li J; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan, China (mainland).
Hou Q; Key Laboratory of Radiation Physics and Technology, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, Sichuan, China (mainland).
Tang B; Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, Sichuan, China (mainland).
Źródło:: Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2022 Mar 09; Vol. 28, pp. e934588. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
Język:: English
Imprint Name(s):: Publication: 2014- : Smithtown, NY : International Scientific Information, Inc.
Original Publication: Warsaw, Poland : Medical Science International
MeSH Terms:: Neoplasm Staging*
Uterine Cervical Neoplasms/*mortality
Disease-Free Survival ; Female ; Global Health ; Humans ; Prognosis ; Survival Rate/trends ; Uterine Cervical Neoplasms/diagnosis
References:: Eur J Obstet Gynecol Reprod Biol. 2002 Nov 15;105(2):170-6. (PMID: 12381482)
JAMA Oncol. 2021 Mar 1;7(3):361-369. (PMID: 33443541)
Eur J Gynaecol Oncol. 2013;34(4):307-10. (PMID: 24020135)
Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
Tumour Biol. 2017 Feb;39(2):1010428317694306. (PMID: 28222668)
PLoS One. 2016 Nov 16;11(11):e0166612. (PMID: 27851819)
World J Surg Oncol. 2019 Aug 2;17(1):132. (PMID: 31375109)
Eur J Surg Oncol. 2019 Apr;45(4):659-665. (PMID: 30685326)
Clin Chim Acta. 2018 Aug;483:296-302. (PMID: 29758203)
J Cancer Res Clin Oncol. 2021 Jun;147(6):1599-1606. (PMID: 33130942)
J Surg Oncol. 2010 Apr 1;101(5):413-7. (PMID: 20127891)
Oncotarget. 2017 Feb 21;8(8):13400-13412. (PMID: 28077792)
Rev Invest Clin. 2017 Sep-Oct;69(5):286-292. (PMID: 29077701)
Cancer Res. 1999 Sep 15;59(18):4525-8. (PMID: 10493500)
Oncotarget. 2017 Apr 11;8(15):24327-24336. (PMID: 28212582)
Int J Gynecol Cancer. 2007 Jul-Aug;17(4):833-42. (PMID: 17367320)
Anticancer Res. 2020 Jan;40(1):451-458. (PMID: 31892600)
Int J Gynaecol Obstet. 2001 Oct;75(1):33-42. (PMID: 11597617)
J BUON. 2019 Jan-Feb;24(1):291-295. (PMID: 30941983)
Cancer. 2003 Apr 15;97(8):1904-8. (PMID: 12673716)
Gynecol Oncol. 2014 Jul;134(1):42-6. (PMID: 24768850)
Mol Clin Oncol. 2015 Mar;3(2):363-366. (PMID: 25798268)
Oncologist. 2010;15(4):405-15. (PMID: 20332143)
Asian Pac J Cancer Prev. 2019 May 25;20(5):1345-1351. (PMID: 31127888)
Gynecol Oncol. 2014 Jan;132(1):81-6. (PMID: 24219981)
Gynecol Oncol. 2009 May;113(2):240-4. (PMID: 19251310)
Oncology. 2017;93(2):106-114. (PMID: 28463843)
PLoS One. 2016 Nov 18;11(11):e0166311. (PMID: 27861522)
Asian Pac J Cancer Prev. 2015;16(14):5951-6. (PMID: 26320478)
Cancer. 2018 Mar 1;124(5):943-951. (PMID: 29211304)
Ginekol Pol. 2020;91(2):57-61. (PMID: 32141049)
Int J Gynecol Cancer. 2019 Jan;29(1):17-22. (PMID: 30640678)
Gynecol Oncol. 2020 Aug;158(2):273-281. (PMID: 32467057)
Acta Obstet Gynecol Scand. 2002 Dec;81(12):1144-51. (PMID: 12519111)
JAMA Netw Open. 2021 May 3;4(5):e216481. (PMID: 33970261)
Biomed Res Int. 2017;2017:2917925. (PMID: 28536694)
Gynecol Oncol. 2011 Dec;123(3):565-70. (PMID: 21963092)
Gynecol Oncol. 2019 Nov;155(2):224-228. (PMID: 31500891)
Arch Gynecol Obstet. 2019 Apr;299(4):1055-1062. (PMID: 30535923)
Biometrics. 1994 Dec;50(4):1088-101. (PMID: 7786990)
Eur J Cancer. 2012 Jul;48(10):1484-94. (PMID: 22244826)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Anticancer Res. 2011 Jun;31(6):2259-64. (PMID: 21737650)
Anticancer Res. 2012 Apr;32(4):1555-61. (PMID: 22493401)
Gynecol Oncol. 2004 May;93(2):458-64. (PMID: 15099962)
Gynecol Oncol. 2011 Jul;122(1):25-32. (PMID: 21514632)
Gynecol Oncol. 2020 Nov;159(2):534-538. (PMID: 32828580)
Int J Gynecol Cancer. 2016 Jul;26(6):1169-75. (PMID: 27206286)
Oncol Rep. 2010 Aug;24(2):511-20. (PMID: 20596641)
Cancer Res Treat. 2018 Jul;50(3):964-974. (PMID: 29081219)
World J Surg Oncol. 2018 Jan 29;16(1):18. (PMID: 29378625)
BMC Cancer. 2019 Jan 7;19(1):22. (PMID: 30616631)
Int J Clin Oncol. 2018 Jun;23(3):522-531. (PMID: 29299705)
Clin Transl Oncol. 2019 Jul;21(7):836-844. (PMID: 30470994)
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1846-54. (PMID: 17009981)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Int J Clin Oncol. 2015 Apr;20(2):345-50. (PMID: 24825458)
Med Sci Monit. 2019 Mar 13;25:1894-1902. (PMID: 30864560)
J Obstet Gynaecol. 2019 Jul;39(5):695-701. (PMID: 31023114)
Medicine (Baltimore). 2020 Apr;99(16):e19714. (PMID: 32311956)
Gynecol Oncol. 2010 Mar;116(3):438-41. (PMID: 19896180)
Eur J Obstet Gynecol Reprod Biol. 2019 Apr;235:6-12. (PMID: 30771718)
J Cancer Res Clin Oncol. 2010 Oct;136(10):1557-62. (PMID: 20169362)
J Cancer Res Clin Oncol. 2009 Feb;135(2):283-90. (PMID: 18626660)
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):204-11. (PMID: 12657125)
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1309-17. (PMID: 7635770)
Gynecol Oncol. 2020 Oct;159(1):164-170. (PMID: 32665147)
BMJ. 2003 Jan 25;326(7382):219. (PMID: 12543843)
Cancer Med. 2018 Jan;7(1):105-113. (PMID: 29193777)
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):834-42. (PMID: 18439764)
Gynecol Oncol. 2001 Sep;82(3):504-9. (PMID: 11520147)
Br J Cancer. 2012 Sep 4;107(6):918-24. (PMID: 22871885)
Int J Clin Oncol. 2004 Dec;9(6):503-9. (PMID: 15616882)
Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):199-204. (PMID: 18037578)
Int J Clin Oncol. 2015 Oct;20(5):989-96. (PMID: 25736530)
N Engl J Med. 2020 Oct 1;383(14):1340-1348. (PMID: 32997908)
Chin J Cancer. 2010 Apr;29(4):431-5. (PMID: 20346221)
Int J Clin Oncol. 2019 Dec;24(12):1612-1619. (PMID: 31236742)
Acta Oncol. 2002;41(5):437-43. (PMID: 12442919)
Int J Gynecol Pathol. 2013 Mar;32(2):228-33. (PMID: 23370644)
Int J Gynecol Cancer. 2019 Mar;29(3):447-452. (PMID: 30833435)
Int J Gynecol Cancer. 2012 Jan;22(1):115-22. (PMID: 21997176)
J Obstet Gynaecol Res. 2017 Jan;43(1):211-219. (PMID: 27862677)
Radiother Oncol. 2013 Jul;108(1):168-73. (PMID: 23684584)
Cell Physiol Biochem. 2018;50(3):1113-1122. (PMID: 30355937)
Int J Gynecol Cancer. 2017 Jun;27(5):987-993. (PMID: 28498238)
J Surg Oncol. 2001 Feb;76(2):133-7. (PMID: 11223840)
J Obstet Gynaecol. 2020 Jul;40(5):699-704. (PMID: 31607197)
PLoS One. 2018 Oct 10;13(10):e0204334. (PMID: 30303986)
Med Oncol. 2014 Jan;31(1):795. (PMID: 24310812)
J Gynecol Oncol. 2020 Jan;31(1):e1. (PMID: 31788991)
J Gynecol Oncol. 2015 Jan;26(1):12-8. (PMID: 25310853)
Am J Obstet Gynecol. 2010 Feb;202(2):174.e1-7. (PMID: 19931041)
J Gynecol Oncol. 2017 Mar;28(2):e19. (PMID: 28028992)
Biomed Res Int. 2020 Nov 12;2020:5791381. (PMID: 33274215)
Ann Oncol. 2003 Oct;14(10):1511-7. (PMID: 14504051)
Medicine (Baltimore). 2018 Jan;97(2):e9323. (PMID: 29480826)
J Obstet Gynaecol. 2017 Apr;37(3):347-354. (PMID: 28141947)
Gynecol Oncol. 2007 Nov;107(2):310-5. (PMID: 17826822)
Medicine (Baltimore). 2019 Oct;98(40):e17301. (PMID: 31577720)
Sci Rep. 2019 Jan 31;9(1):1084. (PMID: 30705329)
Gynecol Oncol. 2000 Nov;79(2):289-93. (PMID: 11063659)
Sci Rep. 2020 Jul 8;10(1):11210. (PMID: 32641736)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):286-92. (PMID: 15086728)
Gynecol Oncol. 2018 Jan;148(1):139-146. (PMID: 29113721)
Gynecol Oncol. 2020 Aug;158(2):266-272. (PMID: 32471646)
Am J Clin Oncol. 2016 Dec;39(6):604-608. (PMID: 24937635)
Int J Gynecol Cancer. 2015 Sep;25(7):1315-21. (PMID: 26186071)
BMC Cancer. 2007 Dec 22;7:234. (PMID: 18154683)
Lancet. 2001 Feb 17;357(9255):539-45. (PMID: 11229684)
Yonsei Med J. 2021 Mar;62(3):231-239. (PMID: 33635013)
Gynecol Oncol. 2001 Jul;82(1):11-6. (PMID: 11426955)
Int J Gynaecol Obstet. 2021 Apr;153(1):56-63. (PMID: 33119174)
J Gynecol Oncol. 2017 Sep;28(5):e58. (PMID: 28657220)
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):613-8. (PMID: 19827880)
Cancer. 2001 Nov 1;92(9):2471-83. (PMID: 11745305)
Asian Pac J Cancer Prev. 2007 Oct-Dec;8(4):530-4. (PMID: 18260723)
Int J Gynecol Cancer. 2013 May;23(4):724-9. (PMID: 23446376)
Acta Obstet Gynecol Scand. 2011 Jul;90(7):737-45. (PMID: 21309753)
Gynecol Oncol. 1999 Dec;75(3):328-33. (PMID: 10600284)
Ann Oncol. 2016 Nov;27(11):2067-2074. (PMID: 27502717)
Medicine (Baltimore). 2018 Jul;97(30):e11711. (PMID: 30045335)
Gynecol Obstet Invest. 2015;79(1):25-33. (PMID: 25278089)
Int J Gynecol Cancer. 2015 Nov;25(9):1656-62. (PMID: 26332391)
Int J Gynecol Cancer. 2012 Feb;22(2):286-90. (PMID: 22146764)
Oncotarget. 2017 Apr 11;8(15):24797-24803. (PMID: 28177889)
Cancer. 1999 Apr 1;85(7):1537-46. (PMID: 10193944)
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):465-70. (PMID: 17309562)
World J Surg Oncol. 2013 Nov 25;11:301. (PMID: 24266990)
Gynecol Oncol. 2012 Mar;124(3):496-501. (PMID: 22120175)
Cancer. 1995 Nov 15;76(10 Suppl):1978-86. (PMID: 8634988)
Cancer. 2011 Feb 15;117(4):768-76. (PMID: 20922801)
Lancet Glob Health. 2020 Feb;8(2):e191-e203. (PMID: 31812369)
Gynecol Oncol. 2000 Aug;78(2):137-42. (PMID: 10926792)
Gynecol Oncol. 2020 Mar;156(3):676-681. (PMID: 31882242)
J Obstet Gynaecol Res. 2012 Nov;38(11):1315-20. (PMID: 22612778)
Asian Pac J Cancer Prev. 2019 Aug 01;20(8):2365-2372. (PMID: 31450907)
Sci Rep. 2019 Mar 1;9(1):3284. (PMID: 30824727)
Tumori. 2018 Mar-Apr;104(2):105-110. (PMID: 29192739)
Int J Gynecol Cancer. 2013 Oct;23(8):1470-5. (PMID: 24257561)
BMC Cancer. 2020 Jul 25;20(1):691. (PMID: 32711484)
Gynecol Oncol. 2017 Dec;147(3):577-584. (PMID: 29110878)
Med Decis Making. 2005 Nov-Dec;25(6):646-54. (PMID: 16282215)
Int J Gynecol Cancer. 2015 Oct;25(8):1476-83. (PMID: 26244756)
Cancer. 2003 Feb 1;97(3):568-74. (PMID: 12548598)
Cancer. 2017 Jul 1;123(13):2404-2412. (PMID: 28464289)
Gynecol Oncol. 2010 Mar;116(3):459-63. (PMID: 20004008)
Front Oncol. 2019 Nov 05;9:1106. (PMID: 31750238)
Br J Cancer. 2010 Aug 24;103(5):613-6. (PMID: 20628380)
Int J Gynecol Cancer. 2016 Sep;26(7):1239-45. (PMID: 27643648)
Medicine (Baltimore). 2016 Aug;95(32):e4381. (PMID: 27512849)
Int J Gynecol Cancer. 2017 Jul;27(6):1228-1236. (PMID: 28604449)
Dis Markers. 2019 Jun 2;2019:6710352. (PMID: 31275450)
Ann Saudi Med. 2020 Jan-Feb;40(1):25-35. (PMID: 32026705)
Int J Gynecol Cancer. 2014 Sep;24(7):1319-25. (PMID: 25033256)
J Gynecol Oncol. 2016 Nov;27(6):e55. (PMID: 27550401)
Anticancer Res. 2016 Jul;36(7):3471-5. (PMID: 27354610)
Int J Gynecol Cancer. 2012 Mar;22(3):490-7. (PMID: 22367323)
Arch Gynecol Obstet. 2019 Oct;300(4):829-839. (PMID: 31385023)
Future Oncol. 2019 Oct;15(30):3467-3481. (PMID: 31580723)
Cancer Res Treat. 2020 Jan;52(1):320-333. (PMID: 31401822)
Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):531-40. (PMID: 9806511)
Gynecol Oncol. 2003 Nov;91(2):395-401. (PMID: 14599872)
Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):769-77. (PMID: 12788184)
Gynecol Oncol. 2014 Mar;132(3):618-23. (PMID: 24486605)
Asian Pac J Cancer Prev. 2011;12(7):1753-6. (PMID: 22126559)
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1862-1869. (PMID: 28534183)
J Minim Invasive Gynecol. 2020 Nov - Dec;27(7):1558-1565. (PMID: 32084588)
J Int Med Res. 2018 Oct;46(10):4082-4091. (PMID: 29963935)
Gynecol Oncol. 2016 Jan;140(1):76-82. (PMID: 26571200)
PLoS One. 2018 Apr 11;13(4):e0192784. (PMID: 29641578)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
Entry Date(s):: Date Created: 20220309 Date Completed: 20220321 Latest Revision: 20220405
Update Code:: 20240104
PubMed Central ID:: PMC8919681
DOI:: 10.12659/MSM.934588
PMID:: 35260545
: Czasopismo naukowe

BACKGROUND Cervical cancer (CC) is the most frequent type of cancer among women and its poor prognosis is a main concern, while the prognostic factors for CC have still remained controversial. We conducted this systematic review and meta-analysis to identify the prognostic significance of clinicopathological factors, influencing overall survival (OS), and event-free survival (EFS) of CC patients. MATERIAL AND METHODS The electronic databases of PubMed, EmBase, and the Cochrane library were systematically searched for identification of eligible studies published until June 2021. The pooled hazard ratio (HR) with 95% confidence interval (CI) were calculated using the random-effects model. Sensitivity and subgroup analyses and assessment of publication bias were also conducted. RESULTS We selected 140 studies that involved 47 965 patients for the meta-analysis. The results revealed that age, cell type, depth of tumor invasion, the International Federation of Gynecology and Obstetrics stage, hemoglobin level, histological grade, leukocytosis, lymph node involvement, lymph-vascular space invasion, neutrophil-to-lymphocyte ratio, parametrial invasion, platelet-to-lymphocyte ratio, resection margin, squamous cell carcinoma antigen level, thrombocytosis, tumor grade, tumor size, and tumor volume were clinicopathological factors influencing OS and EFS of CC patients (P<0.05). CONCLUSIONS This study comprehensively identified the prognostic significance of clinicopathological factors, influencing OS, and EFS of CC patients. However, further large-scale prospective studies should be conducted to verify our findings and develop more accurate prognostic models for CC.

Informacja